Recent Posts

1. 

   Prospecting candidate

   Sanofi

   anonymous

   Apr 25, 2024 at 4:03 PM

2. 

   Eric Brown We Have a Problem

   Can't agree with these posts. I think great leaders and great culture here in my division of firld sales. Problem is the market and our products. Generic maintena in september is just a fact of the market and patent law. Vivitrol patent...

   Alkermes

   anonymous

   Apr 25, 2024 at 4:01 PM

3. 

   2200 cuts coming. How many from sales?

   Cutting overlays or did some last week in cv

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 4:01 PM

4. 

   Elevar

   They are offering a cash LTI component in addition to IC while a pre IPO company then converting to RSUs once listed if all goes well. Perhaps you should ask better interview questions to learn the full compensation package. I prefer cash anyway....

   Biotech Startups

   anonymous

   Apr 25, 2024 at 3:57 PM

5. 

   Sell Otezla and Keep Sotyktu?

   You explain this by documenting marketing fucked up. They should of picked up in the focus panels that dermatology providers are extremely cautious when it comes to prescribing medications with severe side effects when given the option between...

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 3:52 PM

6. 

   SP is the worst

   Now that Daras was pushed aside, will all of the empty suits he brought in be fired?

   Caris Life Sciences

   anonymous

   Apr 25, 2024 at 3:49 PM

7. 

   A New KAM is born

   Back to your original post and the assertion that the company has realized the KAMs are needed and are missed. Well, let me first say, Ha ha ha ha ha ha ahhhhhhh haaaaaa ha. Ha. HA. Now that was on hilarious claim and couldn't be more wrong....

   Alkermes

   anonymous

   Apr 25, 2024 at 3:44 PM

8. + Show More